A case of recurrent ovarian cancer successfully treated with adoptive immunotherapy and lentinan.
BACKGROUND
Immunotherapy is useful for the prevention of the post-operative recurrence of some types of cancer and, in combination with certain anticancer drugs, is expected to prolong survival time. However, the clinical efficacy of immunotherapy alone against advanced cancer has not yet been demonstrated.


METHODS
A 67-year-old woman with ovarian cancer who had undergone post-operative adjuvant chemotherapy suffered from recurrent cancer in the lymph nodes. A partial response to adoptive immunotherapy and the administration of the biological response modifier, lentinan containing beta-glucan as the principal component, was maintained for five months without the use of chemotherapy.


CONCLUSIONS
Adoptive immunotherapy with lentinan alone was potentially useful for the treatment of lymph node metastases from ovarian cancer.
Fujimoto
Katsunada
K
Fukuoka Medical Clinic, 6-18 Tenya-machi, Hakata-ku, Fukuoka, 812-0025, Japan. fujimoto@j-immunother.com
Tomonaga
Masamichi
M
Goto
Shigenori
S
D000368:Aged; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive; D007912:Lentinan / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*
D007912:Lentinan